[Ga]Ga-PSMA-11: The First FDA-Approved Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2021 Aug 28

PMID 34451810

Citations 46

Authors

Ute Hennrich

Matthias Eder

Affiliations

Soon will be listed here.

Abstract

For the positron emission tomography (PET) imaging of prostate cancer, radiotracers targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical practice. Almost 10 years after its discovery, [Ga]Ga-PSMA-11 has been approved in the United States by the Food and Drug Administration (FDA) as the first Ga-radiopharmaceutical for the PET imaging of PSMA-positive prostate cancer in 2020. This radiopharmaceutical combines the peptidomimetic Glu-NH-CO-NH-Lys(Ahx)-HBED-CC with the radionuclide Ga, enabling specific imaging of tumor cells expressing PSMA. Such a targeting approach may also be used for therapy planning as well as potentially for the evaluation of treatment response.

Citing Articles

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.

Xiao W, Jiang W, Chen Z, Huang Y, Mao J, Zheng W Signal Transduct Target Ther. 2025; 10(1):74.

PMID: 40038239 PMC: 11880366. DOI: 10.1038/s41392-024-02107-5.

Advances in prostate-specific membrane antigen-targeted theranostics: from radionuclides to near-infrared fluorescence technology.

Jiang Z, Kadeerhan G, Zhang J, Guo W, Guo H, Wang D Front Immunol. 2025; 15:1533532.

PMID: 39867892 PMC: 11757288. DOI: 10.3389/fimmu.2024.1533532.

Time-efficient HPLC Validation Methodology for the Qualitative Analysis of 68Ga PSMA-11 in Routine Clinical Usage under Isocratic Method.

Tayal S, Gurjar M, Shukla V, Venkatachalam M, Kumar R, Jain Y Indian J Nucl Med. 2025; 39(4):265-271.

PMID: 39790815 PMC: 11708805. DOI: 10.4103/ijnm.ijnm_42_24.

The Application of Prostate Specific Membrane Antigen in the Diagnosis and Treatment of Prostate Cancer: Status and Challenge.

Zeng T, Xie Y, Chai K, Sang H Onco Targets Ther. 2024; 17:991-1015.

PMID: 39564453 PMC: 11573878. DOI: 10.2147/OTT.S485869.

A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer.

Phung S, Zorko N, Soignier Y, Waller R, Shackelford M, Walker J Cancer Immunol Res. 2024; 13(2):258-272.

PMID: 39545924 PMC: 11790377. DOI: 10.1158/2326-6066.CIR-24-0273.

References

Muchnik Kurash M, Gill R, Khairulin M, Harbosh H, Keidar Z . 68Ga-labeled PSMA-11 (68Ga-isoPROtrace-11) synthesized with ready to use kit: normal biodistribution and uptake characteristics of tumour lesions. Sci Rep. 2020; 10(1):3109. PMC: 7033090. DOI: 10.1038/s41598-020-60099-y. View

Kesch C, Vinsensia M, Radtke J, Schlemmer H, Heller M, Ellert E . Intraindividual Comparison of F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study. J Nucl Med. 2017; 58(11):1805-1810. DOI: 10.2967/jnumed.116.189233. View

Brandt M, Cardinale J, Aulsebrook M, Gasser G, Mindt T . An Overview of PET Radiochemistry, Part 2: Radiometals. J Nucl Med. 2018; 59(10):1500-1506. DOI: 10.2967/jnumed.117.190801. View

Eder M, Schafer M, Bauder-Wust U, Hull W, Wangler C, Mier W . 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012; 23(4):688-97. DOI: 10.1021/bc200279b. View

Thisgaard H, Kumlin J, Langkjaer N, Chua J, Hook B, Jensen M . Multi-curie production of gallium-68 on a biomedical cyclotron and automated radiolabelling of PSMA-11 and DOTATATE. EJNMMI Radiopharm Chem. 2021; 6(1):1. PMC: 7790954. DOI: 10.1186/s41181-020-00114-9. View

Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann C . [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012; 39(6):1085-6. DOI: 10.1007/s00259-012-2069-0. View

Zamboglou C, Eiber M, Fassbender T, Eder M, Kirste S, Bock M . Multimodal imaging for radiation therapy planning in patients with primary prostate cancer. Phys Imaging Radiat Oncol. 2021; 8:8-16. PMC: 7807571. DOI: 10.1016/j.phro.2018.10.001. View

Chen Y, Pullambhatla M, Foss C, Byun Y, Nimmagadda S, Senthamizhchelvan S . 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011; 17(24):7645-53. PMC: 3243762. DOI: 10.1158/1078-0432.CCR-11-1357. View

Sterzing F, Kratochwil C, Fiedler H, Sonja Katayama , Habl G, Kopka K . (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2015; 43(1):34-41. PMC: 4771815. DOI: 10.1007/s00259-015-3188-1. View

10.

Zamboglou C, Sachpazidis I, Koubar K, Drendel V, Wiehle R, Kirste S . Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using Ga-HBED-CC PSMA-PET/CT: A planning study based on histopathology reference. Radiother Oncol. 2017; 123(3):472-477. DOI: 10.1016/j.radonc.2017.04.021. View

11.

Pomper M, Musachio J, Zhang J, Scheffel U, Zhou Y, Hilton J . 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging. 2003; 1(2):96-101. DOI: 10.1162/15353500200202109. View

12.

Mease R, Dusich C, Foss C, Ravert H, Dannals R, Seidel J . N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008; 14(10):3036-43. PMC: 3078104. DOI: 10.1158/1078-0432.CCR-07-1517. View

13.

Carlucci G, Ippisch R, Slavik R, Mishoe A, Blecha J, Zhu S . Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership. J Nucl Med. 2021; 62(2):149-155. PMC: 8679592. DOI: 10.2967/jnumed.120.260455. View

14.

Hofman M, Lawrentschuk N, Francis R, Tang C, Vela I, Thomas P . Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020; 395(10231):1208-1216. DOI: 10.1016/S0140-6736(20)30314-7. View

15.

Schuhmacher J, Klivenyi G, Hull W, Matys R, Hauser H, Kalthoff H . A bifunctional HBED-derivative for labeling of antibodies with 67Ga, 111In and 59Fe. Comparative biodistribution with 111In-DPTA and 131I-labeled antibodies in mice bearing antibody internalizing and non-internalizing tumors. Int J Rad Appl Instrum B. 1992; 19(8):809-24. DOI: 10.1016/0883-2897(92)90167-w. View

16.

Zamboglou C, Drendel V, Jilg C, Rischke H, Beck T, Schultze-Seemann W . Comparison of Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics. 2017; 7(1):228-237. PMC: 5196899. DOI: 10.7150/thno.16638. View

17.

Benesova M, Bauder-Wust U, Schafer M, Klika K, Mier W, Haberkorn U . Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. J Med Chem. 2016; 59(5):1761-75. DOI: 10.1021/acs.jmedchem.5b01210. View

18.

Fendler W, Schmidt D, Wenter V, Thierfelder K, Zach C, Stief C . 68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer. J Nucl Med. 2016; 57(11):1720-1725. DOI: 10.2967/jnumed.116.172627. View

19.

Tomlins S, Mehra R, Rhodes D, Cao X, Wang L, Dhanasekaran S . Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2006; 39(1):41-51. DOI: 10.1038/ng1935. View

20.

Pandit-Taskar N, ODonoghue J, Durack J, Lyashchenko S, Cheal S, Beylergil V . A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clin Cancer Res. 2015; 21(23):5277-85. PMC: 4668231. DOI: 10.1158/1078-0432.CCR-15-0552. View